HiberCell’s $60.75 Million Serie A Round Funding

Goodwin advised HiberCell on the deal

HiberCell, a biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, finalized its $60.75 Million Series A funding round led by ARCH Venture Partners. HiberCell is the first company exclusively focused on tumor dormancy detection and therapeutics.

Most patients who succumb to cancer do so because of metastatic cancer. Accumulated evidence has demonstrated that cancer recurrence is driven by dormant disseminated tumor cells (DTCs) that persist undetected in the body for prolonged periods of time. In approaching cancer as a systemic disease, the company seeks to detect and therapeutically target the ‘Achilles heel’ of patient DTCs to prevent or delay metastasis. The company is developing first-in-class therapeutics targeting DTCs originating from solid and liquid cancers.

Goodwin advised HiberCell on the deal with a team including Steve Davis (Picture), Tim Hurley, Brian Waterman and John Taeschler.

Involved fees earner: Stephen Davis – Goodwin Procter; Timothy Hurley – Goodwin Procter; Brian Waterman – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: HiberCell, Inc. ;

Author: Ambrogio Visconti